Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
- PMID: 36961653
- PMCID: PMC10036981
- DOI: 10.1007/s12325-023-02443-y
Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
Abstract
Introduction: Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with hyperphagia, a pathologic insatiable hunger, due to impaired signaling in the melanocortin-4 receptor (MC4R) pathway. The impact of hyperphagia on the lives of patients with BBS and their families has not been fully characterized.
Methods: Patients with BBS or their caregivers who participated in clinical trials of the MC4R agonist setmelanotide (NCT03013543 and NCT03746522) were included in this qualitative study. Telephone interviews were conducted using a semistructured interview guide to explore patient experience and caregiver observations of hyperphagia before and during setmelanotide treatment.
Results: Nineteen interviews (8 patients, 11 caregivers) were conducted. The term "hunger" (rather than "hyperphagia") was used in interviews to ensure common terminology. Before setmelanotide treatment, all participants described their (or their child's) hunger as all-consuming, leading to an obsessive focus on food. Nine participants recalled intense, continuous hunger, and most participants (5 patients, 10 caregivers) reported lack of control with eating. Negative impacts on patients' lives included difficulties with concentration, emotional and physical manifestations, and impaired relationships. All participants experienced or observed improvements in hunger and health outcomes during treatment, the most meaningful of which included weight loss and decrease in obsessive focus on food and food-seeking behaviors. All participants reported improvements in either physical and/or emotional well-being and being satisfied with setmelanotide.
Conclusions: Hyperphagia and resulting food-seeking behaviors have notable negative impacts on quality of life in patients with BBS and caregivers. Setmelanotide improved hyperphagia, reduced body weight and obsessive focus on food, and facilitated improvements in physical and emotional well-being for both patients and caregivers.
Trial registration: NCT03013543 and NCT03746522.
Keywords: Bardet-Biedl syndrome; Disease burden; Hyperphagia; MC4R pathway; Quality of life; Setmelanotide.
© 2023. Rhythm Pharmaceuticals, Inc.
Conflict of interest statement
Claire Ervin, Lindsey Norcross, and Sheri Fehnel’s institution received funding from Rhythm Pharmaceuticals, Inc. for this research. Usha G. Mallya, Robert S. Mittleman, and Matthew Webster were or are full-time employees at the time of this research. As full-time employees, they received stock or stock options. Andrea M. Haqq served on an advisory board for Rhythm Pharmaceuticals, Inc. and Pfizer, is a speaker for Pfizer Canada, and is a principal investigator for clinical trials with Rhythm Pharmaceuticals, Inc. and Levo Therapeutics. Robert M. Haws was contracted by Rhythm Pharmaceuticals, Inc. to conduct study trials; received personal and institutional payments from Rhythm Pharmaceuticals, Inc. and Axovia Therapeutics, LLC for consulting, research, lectures, travel, and lodging; and participated on a data safety monitoring board for Rhythm Pharmaceuticals, Inc.
Similar articles
-
Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.Diabetes Obes Metab. 2024 Apr;26 Suppl 2:25-33. doi: 10.1111/dom.15494. Epub 2024 Feb 21. Diabetes Obes Metab. 2024. PMID: 38383825 Review.
-
Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey.Orphanet J Rare Dis. 2023 Jul 7;18(1):182. doi: 10.1186/s13023-023-02723-4. Orphanet J Rare Dis. 2023. PMID: 37415189 Free PMC article.
-
An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.Expert Opin Pharmacother. 2023 Apr;24(6):667-674. doi: 10.1080/14656566.2023.2199152. Epub 2023 Apr 6. Expert Opin Pharmacother. 2023. PMID: 37013719 Free PMC article.
-
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1. Curr Opin Endocrinol Diabetes Obes. 2023. PMID: 36722447 Free PMC article. Review.
-
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.Orphanet J Rare Dis. 2023 Jan 16;18(1):12. doi: 10.1186/s13023-022-02602-4. Orphanet J Rare Dis. 2023. PMID: 36647077 Free PMC article. Clinical Trial.
Cited by
-
Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management.Obes Pillars. 2024 Apr 22;11:100110. doi: 10.1016/j.obpill.2024.100110. eCollection 2024 Sep. Obes Pillars. 2024. PMID: 38766314 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical